Corvus touts early data on T cell lymphoma drug, makes PhIII plans

Corvus Pharmaceuticals said that its T cell lymphoma drug helped shrink tumors in patients whose cancer had relapsed, according to an early cut of data released Thursday morning.

Of 20 evaluable patients, three had complete responses, and three had partial responses as of May 18. One patient with a complete…

Advertisement — Advertise with Biotech Networks